GOSS

Business Context and Reporting Period

Gossamer Bio, Inc. (GOSS) is a clinical-stage biopharmaceutical company focused on developing seralutinib for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). This Form 10-Q covers the quarterly period ended September 30, 2024. The company operates as a single segment and is currently incurring significant operating losses while advancing its lead candidate through Phase 3 clinical trials.

Key Financial Metrics

Note: Revenue in 2024 is driven entirely by the Chiesi Collaboration Agreement. The company terminated its credit facility in May 2024, paying off the remaining balance.

Material Changes vs. Prior Period

• Revenue Recognition: The company recognized $105.3 million in revenue for the nine months ended September 30, 2024, compared to zero in the prior year. This includes $88.8 million from the sale of licenses and $16.6 million from research and development services under the Chiesi Collaboration Agreement signed in May 2024.
• Net Loss Improvement: Net loss for the nine months ended September 30, 2024, was $23.5 million, a significant improvement from the $131.7 million loss in the same period in 2023, primarily due to the new revenue stream.
• Debt Reduction: The company fully repaid its credit facility with MidCap Financial Trust in May 2024, eliminating the current portion of long-term debt that existed at the end of 2023.
• Operating Expenses: Research and development expenses decreased by $3.0 million year-over-year for the nine-month period, largely due to the cessation of costs for terminated programs, offset by increased spending on the seralutinib Phase 3 trial.

Guidance, Outlook, and Risks

• Collaboration Outlook: Under the Chiesi agreement, the company is eligible for up to $146 million in regulatory milestones and $180 million in sales milestones, plus royalties on net sales outside the U.S. and profit sharing in the U.S.
• Clinical Timeline: The company expects to report topline data from the PROSERA Phase 3 study in PAH in the fourth quarter of 2025. A Phase 3 trial for PH-ILD is expected to commence in mid-2025.
• Liquidity: Management believes existing cash, cash equivalents, and marketable securities ($327.0 million) are sufficient to fund operations for at least the next 12 months.
• Nasdaq Compliance Risk: The company received notice from Nasdaq on September 11, 2024, that its stock price had closed below the $1.00 minimum bid price requirement for 30 consecutive days. It has until March 10, 2025, to regain compliance or risk delisting.
• Future Funding: The company expects to continue incurring significant operating losses and may need to raise additional capital through equity or debt offerings in the future.

Investor Verification Checklist

• Revenue Sustainability: Verify the timing and probability of future milestone payments from Chiesi, as these are contingent on regulatory and commercial success.
• Stock Price Compliance: Monitor the stock price to ensure it meets the $1.00 minimum bid price requirement for 10 consecutive days before March 10, 2025, to avoid delisting.
• Cash Burn Rate: Assess the company's ability to fund the Phase 3 trials and operations through 2025 without dilutive equity raises, given the $327 million liquidity position.
• Debt Obligations: Review the terms of the 5.00% Convertible Senior Notes due 2027 ($200 million principal) and potential conversion scenarios.
• Contract Liabilities: Understand the $64.1 million in deferred revenue (contract liabilities) and the schedule for its recognition over the next 4.3 years.